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intervention may help reinforce health policy worldwide. METHODS: Using a 
Markov model, we performed a cost-effectiveness analysis to estimate the costs, health 
gains, and incremental cost-effectiveness (international dollars [I$] per quality-adjusted 
life year [QALY] gained) of an exercise training program in HF class II and III NYHA 
patients, comparing with standard treatment, assuming a public system perspective in 
Brazil. QALYs were estimated from an outpatient cohort of 318 patients. Treatment 
efﬁcacy was obtained from controlled trials and meta-analysis; treatment costs were 
derived from published data and National Health System reimbursement rates in 
2008. Exercise training costs were obtained from a cardiac rehabilitation center. 
Robusteness of results was tested by Monte Carlo simulation and sensitivity analysis. 
RESULTS: Considering a 35% reduction of mortality with exercise training and an 
annual cost of I$ 1,176 per patient, this strategy had a total cumulative cost of I$ 
25,856 and 4.95 QALYs. Comparing with standard treatment, which had a total cost 
of I$ 16,758 and 4.34 QALYs, the incremental cost per QALY of exercise training 
was I$ 14,965. Results were sensitive to intervention-related costs and effect size. 
Considering the results of the HF-ACTION trial, in a time-limited exercise program 
with a 11% combined event (all-cause mortality or hospitalization) reduction and an 
exercise cost of I$ 470 per patient, incremental cost-effectiveness ratio would be I$ 
19,828/QALY. CONCLUSIONS: Under several assumptions, exercise training 
appeared to be cost-effective, and to offer good value for money compared to other 
well-accepted HF treatment strategies. The results support implementing such inter-
vention as part of public health efforts to improve HF management.
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OBJECTIVES: In the INFORCE study, treatment with ezetimibe/simvastatin (Eze/
Simva) 10/40 mg/day was superior to doubling the statin dose in reducing total cho-
lesterol (TC) among inpatients with suspected coronary events already receiving a 
statin (stratiﬁed into 3 potency strata at baseline). The purpose of this analysis was 
to evaluate the cost-effectiveness of Eze/Simva in this population by translating reduc-
tions in the observed TC: high-density lipoprotein cholesterol ratio into projected 
lifetime costs and beneﬁts. METHODS: A Markov model (Cook et al 2004) was used 
to project lifetime costs and beneﬁts based on patients’ cardiovascular risk factor 
proﬁles and actual lipid values at baseline and endpoint (12 weeks). Inputs for car-
diovascular event costs and age-speciﬁc utilities for health states were based on a 2006 
National Institute of Health and Clinical Excellence submission for Eze and age-spe-
ciﬁc non–CHD mortality rates (2006) derived from UK Ofﬁce of National Statistics 
mortality data. RESULTS: At baseline, the Eze/Simva group (N  195) had a higher 
mean [SD] TC (4.33 [0.89] mmol/L) than the double-statin group (N  189; 4.16 
[0.80] mmol/L). In the pooled-data analysis adjusted for baseline proﬁle, Eze/Simva 
conferred 0.218 discounted (3.5%) incremental quality-adjusted life year (QALY) at 
a discounted (3.5%) incremental cost of £2,524, for an Incremental Cost-Effectiveness 
Ratio (ICER) of £11,571/QALY. Similar data were observed in each stratum of statin 
LDL-C–lowering potency, with ICER values £15,000/QALY for each comparison 
of Eze/Simva to statins: Eze/Simva was cost-effective in the low-potency (£13,552/
QALY), medium-potency (£11,930/QALY), and high-potency (£10,148/QALY) statin 
strata in adjusted analyses. On bootstrapping analysis, the ICER for Eze/Simva therapy 
was £20,000/QALY in 99% of replicates for the adjusted analysis. CONCLUSIONS: 
Among UK inpatients evaluated for coronary events, switching to Eze/Simva 10/40 mg 
is projected to be a cost-effective treatment alternative (vs doubling the statin dose) 
based on a commonly applied UK ICER threshold (£20,000–£30,000).
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OBJECTIVES: Statin dose escalation to reach low-density lipoprotein cholesterol 
(LDL-C) goals is an established practice. This study analyzes the health economic 
impact of titrating patients to a target LDL-C of 100 mg/dl as recommended by current 
guidelines. First-line brand rosuvastatin and ﬁrst-line generic simvastatin protocols are 
compared. METHODS: A published state-transition model was used, linking age, 
smoking status, systolic blood pressure, and total cholesterol (TC) to fatal CVD risk 
using the Belgian SCORE (primary prevention) and Framingham (secondary preven-
tion) equations. Non-fatal risk was based on landmark prevention trials. Patient 
LDL-C levels (mean/SD, before/after treatment start) were based on the STELLAR 
trial for simvastatin 20/40/80 mg and rosuvastatin 10/20/40 mg. Hence, consistent 
with the STELLAR trial a baseline LDL-C value (mg/dl) of (mean / SD) 189 / 19 
was applied. Other patient data were based on the DISCOVERY-BELUX trial that 
included Belgian patients. Resource use and unit costs were based on literature and 
ofﬁcial reimbursement tariffs. Patient groups starting on either rosuvastatin (10 mg) 
or simvastatin (20 mg) were compared. Patients not reaching LDL-C target were 
switched to the next higher dose of the same statin. Simvastatin 80 mg patients not 
reaching target were switched to 20 mg and if needed 40 mg of rosuvastatin. Cost-
effectiveness results were reported as EUR 2009 (direct medical costs from a public 
payer perspective) per Life Year gained (LYg) for a time horizon of 20 years. 
RESULTS: EUR/LYg values of 56,481 and 43,884 were found for respectively primary 
and secondary settings, well below some of the ICER values reported for other health 
care interventions attracting public reimbursement. Model explorations indicated that 
cost-effectiveness improved for lower LDL-C targets and higher baseline patient LDL-
C levels. CONCLUSIONS: Exclusive titration by rosuvastatin compared to starting 
patients ﬁrst on simvastatin, is likely to be cost-effective in patients with elevated 
LDL-C levels both in primary and secondary prevention.
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OBJECTIVES: This study aims to verify the economic feasibility of clopidogrelaspirin 
combination therapy by comparing the reduction in ischemic heart disease develop-
ment, and corresponding costs of aspirin monotherapy and clopidogrelaspirin com-
bination therapy (CT) in Korean acute coronary syndrome (ACS) patients. METHODS: 
We conducted a cost-effectiveness analysis of 3-years clopidogrelaspirin CT in ACS 
patients from a social perspective, taking into account all direct medical costs, direct 
non-medical costs, and indirect costs that occur during the course of clopidogrelaspirin 
CT and compared this to aspirin monotherapy. The effect of clopidogrel addition was 
applied, based on data from the Clopidogrel in Unstable angina to prevent Recurrent 
ischemic Events (CURE) study. The transition probability of Markov model was esti-
mated using health insurance claim data and records in the Korean Cause of Death 
Registry for the years 2001–2003. RESULTS: The long-term Markov model analysis 
revealed that the effect of clopidogrelaspirin CT compared with aspirin monotherapy 
in ACS patients was 0.207 life-years gained (LYG) and that the incremental cost-
effectiveness ratio analyzed as incremental costs per LYG was US$ 5,154.07. In addi-
tion, sensitivity analysis demonstrated that the relative risk and discount rate for 
cardiovascular events (acute myocardial infarction, stroke and cardiovascular death) 
were the variables that mainly affected the study results. CONCLUSIONS: A 38-year 
follow-up study of the 3-years effect of clopidogrelaspirin CT in Korea reveals that 
clopidogrel CT is a cost-effective alternative to aspirin monotherapy. Additionally, 
these results provide an economic justiﬁcation for recommending clopidogrel CT in 
the treatment of ACS patients within the Korean context.
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OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁable cardiovascular risk factor. Ivabradine is a speciﬁc HR lowering agent 
indicated in chronic stable angina (SA) patients with normal sinus rhythm, contrain-
dicated or intolerant to beta-blockers. This study aimed to estimate the cost-effective-
ness of ivabradine versus generic amlodipine in such patients, from the Finnish societal 
perspective. METHODS: A Markov chain Monte Carlo stochastic simulation model 
was used to estimate the inﬂuence of HR lowering in cardiovascular morbidity and 
mortality and its economic consequences. Ivabradine, 7.5 mg twice a day, was com-
pared against amlodipine, 10 mg once a day. HR distribution was modelled as a 
gamma function and survival and time to hospitalization were modelled with weibull 
functions. Only patients with resting HR       70 bpm were included. Events considered      
were acute myocardial infarction, stroke, heart failure and death, as well as revascu-
larization procedures (coronary artery bypass graft and percutaneous coronary inter-
ventions). Finnish setting was considered, including only direct costs, derived from the 
2006 Finnish Guidelines for Healthcare Unit Costs. Effectiveness was measured in life      
years (LY) and quality-adjusted life years (QALY). Time horizon was set at 20 years 
and discount rate was 5%/year for costs and effectiveness. RESULTS: For each 100 
patients using ivabradine in comparison with amlodipine we estimate a 36 LYs 
(95%CI: [18;57]) or 30 QALYs (95%CI: [17;47]) gain. Annual incremental cost per 
patient was a226 (95%CI: [201;243]). Incremental cost-effectiveness ratios for ivabra-
dine utilization were a12,886/LY and a15,060/QALY. For high levels of certainty     
(90%), willingness to pay for ivabradine’s beneﬁts didn’t exceed a24,000, regardless 
of the effectiveness measure considered. CONCLUSIONS: Ivabradine is a cost-
 effective alternative for the treatment of SA when compared to generic amlodipine     
in a Finnish setting of patients with contraindication or intolerance to beta-blockers         
and resting HR  70 bpm. 
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OBJECTIVES: High resting heart rate (HR) has been increasingly accepted as a 
modiﬁable cardiovascular risk-factor. Ivabradine has shown speciﬁc HR lowering 
properties and is indicated in chronic stable angina (SA) patients with normal sinus 
rhythm having a contraindication or intolerance for beta-blockers. The aim of this 
